Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Pediatr Pulmonol. 2021 May;56(5):1173-1181. doi: 10.1002/ppul.25188. Epub 2020 Dec 14.
Noninvasive ventilation (NIV) is a first-line therapy for sleep-related breathing disorders and chronic respiratory insufficiency. Evidence about predictors that may impact long-term NIV outcomes, however, is scarce. The aim of this study is to determine demographic, clinical, and technology-related predictors of long-term NIV outcomes.
A 10-year multicentred retrospective review of children started on long-term continuous or bilevel positive airway pressure (CPAP or BPAP) in Alberta. Demographic, technology-related, and longitudinal clinical data were collected. Long-term outcomes examined included ongoing NIV use, discontinuation due to improvement in underlying conditions, switch to invasive mechanical ventilation (IMV) or death, patient/family therapy declination, transfer of services, and hospital admissions.
A total of 622 children were included. Both younger age and CPAP use predicted higher likelihood for NIV discontinuation due to improvement in underlying conditions (p < .05 and p < .01). Children with upper airway disorders or bronchopulmonary dysplasia were less likely to continue NIV (p < .05), while presence of central nervous system disorders had a higher likelihood of hospitalizations (p < .01). The presence of obesity/metabolic syndrome and early NIV-associated complications predicted higher risk for NIV declination (p < .05). Children with more comorbidities or use of additional therapies required more hospitalizations (p < .05 and p < .01) and the latter also predicted higher risk for being switched to IMV or death (p < .001).
Demographic, clinical data, and NIV type impact long-term NIV outcomes and need to be considered during initial discussions about therapy expectations with families. Knowledge of factors that may impact long-term NIV outcomes might help to better monitor at-risk patients and minimize adverse outcomes.
无创通气(NIV)是治疗睡眠相关呼吸障碍和慢性呼吸功能不全的一线治疗方法。然而,关于可能影响长期 NIV 结局的预测因素的证据很少。本研究旨在确定长期 NIV 结局的人口统计学、临床和技术相关预测因素。
对艾伯塔省开始长期持续或双水平气道正压通气(CPAP 或 BPAP)的儿童进行了为期 10 年的多中心回顾性研究。收集了人口统计学、技术相关和纵向临床数据。检查的长期结局包括持续使用 NIV、因基础疾病改善而停用、转为有创机械通气(IMV)或死亡、患者/家庭治疗拒绝、服务转移和住院。
共纳入 622 名儿童。年龄较小和 CPAP 使用均预测因基础疾病改善而停用 NIV 的可能性更高(p<0.05 和 p<0.01)。患有上呼吸道疾病或支气管肺发育不良的儿童继续使用 NIV 的可能性较低(p<0.05),而存在中枢神经系统疾病的儿童住院的可能性更高(p<0.01)。肥胖/代谢综合征和早期 NIV 相关并发症的存在预测了 NIV 拒绝的更高风险(p<0.05)。合并症较多或使用额外治疗的儿童需要更多的住院治疗(p<0.05 和 p<0.01),后者也预测了更高的风险转换为 IMV 或死亡(p<0.001)。
人口统计学、临床数据和 NIV 类型会影响长期 NIV 结局,因此在与患者家属讨论治疗预期时需要考虑这些因素。了解可能影响长期 NIV 结局的因素有助于更好地监测高危患者并最小化不良结局。